HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Blood

• Publication date

  2016-11-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2016-04-711176PMID 27742706
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Postibrutinib outcomes in patients with mantle cell lymphoma.

  2016cited by this paper
• Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

  2015cited by this paper
• Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

  2015cited by this paper
• Resistance to HSP90 inhibition involving loss of MCL1 addiction

  2015influential reference
• Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma

  2015cited by this paper
• Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

  2014cited by this paper
• Ibrutinib resistance in chronic lymphocytic leukemia.

  2014cited by this paper
• Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.

  2014cited by this paper
• MultiNotch MS3 Enables Accurate, Sensitive, and Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes

  2014cited by this paper
• UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib

  2014cited by this paper
• FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism

  2014cited by this paper
• Quantitative Temporal Viromics: An Approach to Investigate Host-Pathogen Interaction

  2014cited by this paper
• Targeting Bruton's tyrosine kinase in B cell malignancies

  2014cited by this paper
• Measurement, geospatial, and mechanistic models of public health hazard vulnerability and jurisdictional risk.

  2014cited by this paper
• Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

  2014cited by this paper
• Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic flux.

  2014cited by this paper
• Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX

  2013cited by this paper
• Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma

  2013influential reference
• Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

  2013cited by this paper
• First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors

  2013cited by this paper
• Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

  2012cited by this paper
• Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.

  2012cited by this paper
• BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation

  2012cited by this paper
• LC-MS/MS Analysis of Differentially Expressed Glioblastoma Membrane Proteome Reveals Altered Calcium Signaling and Other Protein Groups of Regulatory Functions*

  2012cited by this paper
• The HSP90 Inhibitor NVP-AUY922 Radiosensitizes by Abrogation of Homologous Recombination Resulting in Mitotic Entry with Unresolved DNA Damage

  2012cited by this paper
• FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.

  2012cited by this paper
• Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

  2012cited by this paper
• Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

  2012cited by this paper
• Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

  2011cited by this paper
• Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

  2011cited by this paper
• Quantitative Proteomics Reveals That Hsp90 Inhibition Preferentially Targets Kinases and the DNA Damage Response*

  2011cited by this paper
• Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.

  2011cited by this paper
• Hsp90 and co-chaperones twist the functions of diverse client proteins.

  2010cited by this paper
• Targeting the dynamic HSP90 complex in cancer

  2010cited by this paper
• Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation.

  2010cited by this paper
• HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.

  2010cited by this paper
• Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia

  2009cited by this paper
• Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.

  2008cited by this paper
• Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-κB pathway and promotes lymphomagenesis

  2008cited by this paper
• Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics

  2007cited by this paper
• Drugging the Cancer Chaperone HSP90

  2007cited by this paper
• Geldanamycin Induces Heat Shock Protein Expression Through Activation of HSF1 in K562 Erythroleukemic Cells

  1999cited by this paper
• Heat shock-induced accumulation of 70-kDa stress protein (HSP70) can protect ATP-depleted tumor cells from necrosis.

  1995cited by this paper

• NK cell immunotherapy administered at the time of HIV recrudescence is associated with viral control

  2025cites this paper
• Potential benefits of combined treatment with Hsp90 inhibitor AUY922 and cisplatin for overcoming drug resistance in nasopharyngeal carcinoma.

  2025cites this paper
• Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma

  2024cites this paper
• The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma

  2024cites this paper
• (Re)Minding the obvious

  2023cites this paper
• Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma

  2023cites this paper
• Heat-Shock Proteins in Leukemia and Lymphoma: Multitargets for Innovative Therapeutic Approaches

  2023cites this paper
• BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

  2022cites this paper
• HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib

  2022cites this paper
• HSP90 inhibition downregulates DNA replication and repair genes via E2F1 repression

  2021cites this paper
• P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib

  2021cites this paper
• Heat Shock Proteins in Lymphoma Immunotherapy

  2021cites this paper
• Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma

  2021cites this paper
• HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias

  2021cites this paper
• Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.

  2021cites this paper
• Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers

  2021cites this paper
• Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro

  2021cites this paper
• Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia

  2019cites this paper
• Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.

  2019cites this paper
• L-Lactate dehydrogenase B may be a predictive marker for sensitivity to anti-EGFR monoclonal antibodies in colorectal cancer cell lines.

  2019cites this paper
• Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins

  2019cites this paper
• Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells

  2019cites this paper
• Destabilization of ROR1 enhances activity of ibrutinib against chronic lymphocytic leukemia in vivo.

  2019cites this paper
• Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on

  2019cites this paper
• Anaplastic Large Cell Lymphoma

  2019cites this paper
• Kinobead profiling reveals reprogramming of B-cell receptor signaling in response to therapy within primary CLL cells

  2019cites this paper
• Enhancing natural killer cell function with gp41-targeting bispecific antibodies to combat HIV infection

  2019cites this paper
• Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.

  2018cites this paper
• Proteomic Profiling of Hsp90 Inhibitors.

  2018cites this paper
• BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells

  2018cites this paper
• NK Cells in HIV-1 Infection: From Basic Science to Vaccine Strategies

  2018cites this paper
• Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.

  2018cites this paper
• Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.

  2018cites this paper
• Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects

  2018influential citation
• Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All.

  2018cites this paper
• One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells

  2017cites this paper
• Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells

  2017cites this paper
• Physiopathologie du lymphome à cellules du manteau : de la mécanistique aux modèles précliniques

  2017cites this paper
• HSP90, a chaperone that can make you SYK.

  2017cites this paper
• Patient-derived tumor xenografts of lymphoproliferative disorders: are they surrogates for the human disease?

  2017cites this paper
• Novel therapies for relapsed/refractory mantle cell lymphoma.

  2017cites this paper